Enhancing Inpatient Psychotherapeutic Treatment With Online Self-help : Acceptance and Efficacy
Primary Purpose
Depression
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
deprexis®
Information
Sponsored by

About this trial
This is an interventional treatment trial for Depression
Eligibility Criteria
Inclusion Criteria:
- Inpatient treatment
- Private internet access
- Informed consent
- Age between 18 and 65 years
- Knowledge of the German language
- Score in the BDI-II > 13 and clinical diagnosis of a depression (ICD-10: F32.x, F33.x, F34.1, F43.2) verified by the inpatient therapist
Exclusion Criteria:
- Psychosis
- Current alcohol or drug dependency
- Borderline, antisocial, schizoid or schizotypal personality disorder
- Anorexia nervosa
- Life time diagnosis of a schizophrenia, schizoaffective , bipolar oder organic psychic disorder
Sites / Locations
- Psychosomatic Clinic Bad Neustadt
- University Medical Center, Department of Psychosomatic Medicine and Psychotherapy, Johannes Gutenberg University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
deprexis®
Information
Arm Description
Patients in this arm use deprexis® as an additional treatment during their inpatient stay and as an aftercare intervention.
Patients in this arm receive online information about depression as a placebo comparator in addition to their treatment during their inpatient stay and as an aftercare intervention.
Outcomes
Primary Outcome Measures
Reduction of depression measured with the "Beck's Depression Inventory" (BDI-II)
Secondary Outcome Measures
Reduction of depression measured with the depression scale of the "Patient Health Questionnaire" (PHQ-9)
Reduction of depression measured with the "Beck's Depression Inventory" (BDI-II)
Reduction of anxiety measured with the "Generalized Anxiety Disorder Scale" (GAD-7)
Reduction of dysfunctional depression related cognitions measured with the "Dysfunctional Attitude Scale" (DAS)
Improved self-esteem measured with the "Rosenberg Self-Esteem Scale" (RSE)
Improved quality of life measured with the "European Health Interview Survey Quality of Life-8" (EUROHIS-QOL 8)
Improved working ability measured with the short form of the "Work Ability Index" (WAI)
Acceptance and utilization of deprexis® measured with a self devised questionnaire
Acceptance and utilization of the information used in the placebo condition measured with a self devised questionnaire
Degree of childhood traumas measured with the "Childhood Trauma Questionnaire" (CTQ)
Assumption that childhood traumas, assessed at the beginning of treatment, have a moderating effect on the reduction in the primary outcome measure.
Degree of structural deficits measured with the short form of the OPD-Structure Questionnaire (OPD-SFK)
Assumption that structural deficits, as assessed with the OPD-SFK questionnaire at the beginning of treatment have a moderating effect on the reduction in the primary outcome measure.
Therapeutic alliance between participant and inpatient psychotherapist measured with the "Helping Alliance Questionnaire" (HAQ).
Course of mood, depressiveness and utilization of units
Utilization of other treatments after the end of inpatient treatment
Satisfaction with inpatient treatment
Willingness to pay
Remission from depression
BDI score below the cutoff of 13 and a reliable change regarding Reliable Change Index (RCI)
Full Information
NCT ID
NCT02196896
First Posted
July 16, 2014
Last Updated
March 16, 2017
Sponsor
Johannes Gutenberg University Mainz
Collaborators
Rhön-Klinikum AG
1. Study Identification
Unique Protocol Identification Number
NCT02196896
Brief Title
Enhancing Inpatient Psychotherapeutic Treatment With Online Self-help : Acceptance and Efficacy
Official Title
Enhancing Inpatient Psychotherapeutic Treatment With Online Self Help in a Randomised Controlled Trial: Acceptance and Efficacy
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
June 2014 (undefined)
Primary Completion Date
November 2016 (Actual)
Study Completion Date
November 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Johannes Gutenberg University Mainz
Collaborators
Rhön-Klinikum AG
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine the acceptance and efficacy of the online self-help program deprexis® for depressed patients in reducing the clinical symptoms of their depression. The patients of the experimental group use deprexis® for 90 days, the patients of the placebo group receive weekly online information about depression for 90 days as well. Both groups receive their treatment in addition to their regular inpatient psychosomatic treatment and as an aftercare intervention.The investigators hypothesize that the online self-help group achieves a greater reduction of depression compared to the control group.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
229 (Actual)
8. Arms, Groups, and Interventions
Arm Title
deprexis®
Arm Type
Experimental
Arm Description
Patients in this arm use deprexis® as an additional treatment during their inpatient stay and as an aftercare intervention.
Arm Title
Information
Arm Type
Placebo Comparator
Arm Description
Patients in this arm receive online information about depression as a placebo comparator in addition to their treatment during their inpatient stay and as an aftercare intervention.
Intervention Type
Other
Intervention Name(s)
deprexis®
Intervention Description
Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
Intervention Type
Other
Intervention Name(s)
Information
Intervention Description
The patients receive online information about depression once a week for 90 days.
Primary Outcome Measure Information:
Title
Reduction of depression measured with the "Beck's Depression Inventory" (BDI-II)
Time Frame
Three months after randomization
Secondary Outcome Measure Information:
Title
Reduction of depression measured with the depression scale of the "Patient Health Questionnaire" (PHQ-9)
Time Frame
Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Title
Reduction of depression measured with the "Beck's Depression Inventory" (BDI-II)
Time Frame
Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Title
Reduction of anxiety measured with the "Generalized Anxiety Disorder Scale" (GAD-7)
Time Frame
Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Title
Reduction of dysfunctional depression related cognitions measured with the "Dysfunctional Attitude Scale" (DAS)
Time Frame
Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Title
Improved self-esteem measured with the "Rosenberg Self-Esteem Scale" (RSE)
Time Frame
Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Title
Improved quality of life measured with the "European Health Interview Survey Quality of Life-8" (EUROHIS-QOL 8)
Time Frame
Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Title
Improved working ability measured with the short form of the "Work Ability Index" (WAI)
Time Frame
Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Title
Acceptance and utilization of deprexis® measured with a self devised questionnaire
Time Frame
End of inpatient treatment (average 6 weeks), three months after randomization
Title
Acceptance and utilization of the information used in the placebo condition measured with a self devised questionnaire
Time Frame
End of inpatient treatment (average 6 weeks), three months after randomization
Title
Degree of childhood traumas measured with the "Childhood Trauma Questionnaire" (CTQ)
Description
Assumption that childhood traumas, assessed at the beginning of treatment, have a moderating effect on the reduction in the primary outcome measure.
Time Frame
Randomization
Title
Degree of structural deficits measured with the short form of the OPD-Structure Questionnaire (OPD-SFK)
Description
Assumption that structural deficits, as assessed with the OPD-SFK questionnaire at the beginning of treatment have a moderating effect on the reduction in the primary outcome measure.
Time Frame
Randomization
Title
Therapeutic alliance between participant and inpatient psychotherapist measured with the "Helping Alliance Questionnaire" (HAQ).
Time Frame
Randomization, end of inpatient treatment (average 6 weeks)
Title
Course of mood, depressiveness and utilization of units
Time Frame
During inpatient treatment (average 6 weeks)
Title
Utilization of other treatments after the end of inpatient treatment
Time Frame
Six months after randomization
Title
Satisfaction with inpatient treatment
Time Frame
End of inpatient treatment (average 6 weeks)
Title
Willingness to pay
Time Frame
Three months after randomization
Title
Remission from depression
Description
BDI score below the cutoff of 13 and a reliable change regarding Reliable Change Index (RCI)
Time Frame
End of inpatient treatment (average 6 weeks), three months after randomization, six months after randomization
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Inpatient treatment
Private internet access
Informed consent
Age between 18 and 65 years
Knowledge of the German language
Score in the BDI-II > 13 and clinical diagnosis of a depression (ICD-10: F32.x, F33.x, F34.1, F43.2) verified by the inpatient therapist
Exclusion Criteria:
Psychosis
Current alcohol or drug dependency
Borderline, antisocial, schizoid or schizotypal personality disorder
Anorexia nervosa
Life time diagnosis of a schizophrenia, schizoaffective , bipolar oder organic psychic disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manfred E Beutel, Prof. Dr.
Organizational Affiliation
University Medical Center, Department of Psychosomatic Medicine and Psychotherapy, Johannes Gutenberg University Mainz
Official's Role
Principal Investigator
Facility Information:
Facility Name
Psychosomatic Clinic Bad Neustadt
City
Bad Neustadt
State/Province
Bavaria
ZIP/Postal Code
97616
Country
Germany
Facility Name
University Medical Center, Department of Psychosomatic Medicine and Psychotherapy, Johannes Gutenberg University
City
Mainz
State/Province
Rhineland-Palatinate
ZIP/Postal Code
55131
Country
Germany
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
31651403
Citation
Zwerenz R, Baumgarten C, Becker J, Tibubos A, Siepmann M, Knickenberg RJ, Beutel ME. Improving the Course of Depressive Symptoms After Inpatient Psychotherapy Using Adjunct Web-Based Self-Help: Follow-Up Results of a Randomized Controlled Trial. J Med Internet Res. 2019 Oct 24;21(10):e13655. doi: 10.2196/13655.
Results Reference
derived
PubMed Identifier
25872505
Citation
Zwerenz R, Becker J, Knickenberg RJ, Hagen K, Dreier M, Wolfling K, Beutel ME. Enhancing inpatient psychotherapeutic treatment with online self-help: study protocol for a randomized controlled trial. Trials. 2015 Mar 17;16:98. doi: 10.1186/s13063-015-0620-6.
Results Reference
derived
Learn more about this trial
Enhancing Inpatient Psychotherapeutic Treatment With Online Self-help : Acceptance and Efficacy
We'll reach out to this number within 24 hrs